Omics-driven Research on the Gut-Oral Microbiome, Metabolome, Lifestyle, and Clinical Integration in Korean Inflammatory Bowel Disease

Summary

The inflammatory bowel disease (IBD) is a condition that afflects approximately 5 million people worldwide, with 1.4 million in the US and 2.2 million in Europe. By 2030, it is predicted that up to 1% of the entire Western population will have this disease. Notably, IBD encompasses conditions like Crohn's disease (CD) and Ulcerative colitis (UC). The emergence of this disease in non-Western countries is attributed to the rapid urbanization and industrialization which has led to the adoption of Westernized diets, an increase in the use of antibiotics early in life, and air pollution. These factors are suspected to induce changes in the gut microbiome, contributing to the rise of IBD. However, as an immune-mediated chronic intestinal disease, it is a multifactorial condition triggered by genetic mutations, gut microbial features, and environmental factors. Despite numerous studies, the exact causes remain insufficiently understood, emphasizing the importance of research and development to significantly benefit the health of the rapidly increasing patients. The study aims to construct a multi-omics analysis platform, including gut microbiome analysis, using biosamples collected from Korean patients with inflammatory bowel disease (IBD) and their families. Through this platform, comparative clinical research will be conducted to elucidate the pathophysiology of the disease and develop potential biomarkers.

Conditions

• Inflammatory Bowel Disease (IBD)

Sponsors & Collaborators

• Kangbuk Samsung Hospital

  collaborator OTHER

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  collaborator OTHER

• Inje University Haeundae Paik Hospital

  collaborator OTHER

• Yeungnam University Hospital

  collaborator OTHER

• Kyungpook National University Hospital

  collaborator OTHER

• Chonnam National University Hospital

  collaborator OTHER

• Wonkwang University Hospital

  collaborator OTHER

• Daejeon St. Mary's hospital

  collaborator OTHER

• Dankook University

  collaborator OTHER

• Kyung Hee University Hospital at Gangdong

  collaborator OTHER

• Inje University Ilsan Paik Hospital

  collaborator OTHER

• Hanyang University

  collaborator OTHER

• Soon Chun Hyang University

  collaborator OTHER

• Chung-Ang University Gwangmyeong Hospital

  collaborator OTHER

• Keimyung University Dongsan Medical Center

  collaborator OTHER

• Chang Kyun Lee

  lead OTHER

Principal Investigators

• Chang Kyun Lee, MD, PhD · Kyunghee University Medical Center

Eligibility

Min Age

13 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-10-04

Primary Completion

2028-08-01

Completion

2028-08-01

Countries

• South Korea

Study Locations